Multiple drug resistance due to resistance to stem cells and stem cell treatment progress in cancer (Review)

Experimental and Therapeutic Medicine

Volumn 9, Issue 2, 2015, Pages 289-293

  Di, Chong ^a   Zhao, Yaodong ^a  

^a TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

Author keywords

Adenosine triphosphatebinding cassette transporter; Aldehydes dehydrogenase; Cancer stem cell; Epithelial to mesenchymal transition; Microenvironment; Multiple drug resistance

Indexed keywords

1, 2, 3, 4, 6, 7, 12, 12A OCTAHYDRO 6 ISOBUTYL 9 METHOXY 1, 4 DIOXOPYRAZINO [1', 2':1, 6] PYRIDO [3, 4 B] INDOLE 3 PROPANOIC ACID TERT BUTYL ESTER; ABAMECTIN; ABC TRANSPORTER; ALDEHYDE DEHYDROGENASE ISOENZYME 1; ALDEHYDE DEHYDROGENASE ISOENZYME 2; BEVACIZUMAB; BIRICODAR; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CURCUMIN; CYCLOSPORIN; DISULFIRAM; DOXORUBICIN; FLUOROURACIL; FUMITREMORGIN C; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; NICARDIPINE; NIGERICIN; OXALIPLATIN; PIPERINE; POLYPHENOL; PROTEIN KINASE B; SALINOMYCIN; TARIQUIDAR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINCRISTINE; ZOSUQUIDAR;

APOPTOSIS; ARTICLE; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER STEM CELL; CELL PROLIFERATION; CHEMOTHERAPY; COLON CANCER; COLON CARCINOMA; COLORECTAL CANCER; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA CELL; HEDGEHOG; HUMAN; HYPOXIA; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; MULTIDRUG RESISTANCE; NASOPHARYNX CARCINOMA; NEOPLASM; OVARY CANCER; PROSTATE CARCINOMA; RECEPTOR DOWN REGULATION; SCHISANDRA; SQUAMOUS CELL CARCINOMA; STEM CELL TRANSPLANTATION; TUMOR MICROENVIRONMENT; TUMOR RESISTANCE;

EID: 84918791885     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.2141     Document Type: Article

References (58)

1. Reya T, Morrison SJ, Clarke MF and Weisssman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001.
2. Park CH, Bergsagel DE and McCulloch EA: Mouse myeloma tumor stem cells: a primary cell culture assay. J Natl Cancer Inst 46: 411-422, 1971.
3. Gupta PB, Chaffer CL and Weinberg RA: Cancer stem cells: mirage or reality? Nat Med 15: 1010-1012, 2009.
4. Merlos-Suárez A, Barriga FM, Jung P, et al: The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 8: 511-524, 2011.
5. Fletcher JI, Haber M, Henderson MJ and Norris MD: ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 10: 147-156, 2010.
6. Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627, 2002.
7. Jin Y, Bin ZQ, Qiang H, et al: ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma. J Cancer Res Clin Oncol 135: 1369-1376, 2009.
8. Wang B, Yang H, Huang YZ, Yan RH, Liu FJ and Zhang JN: Biologic characteristics of the side population of human small cell lung cancer cell line H446. Chin J Cancer 29: 254-260, 2010.
9. Adhikari AS, Agarwal N, Wood BM, et al: CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res 70: 4602-4612, 2010.
10. Hu L, McArthur C and Jaffe RB: Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer 102: 1276-1283, 2010.
11. Tokar EJ, Qu W, Liu J, et al: Arsenic-specific stem cell selection during malignant transformation. J Natl Cancer Inst 102: 638-649, 2010.
12. Wang J, Guo LP, Chen LZ, Zeng YX and Lu SH: Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res 67: 3716-3724, 2007.
13. Hu C, Li H, Li J, et al: Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis 29: 2289-2297, 2008.
14. Allen JD, van Loevezijn A, Lakhai JM, et al: Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1: 417-425, 2002.
15. Cisternino S, Mercier C, Bourasset F, Roux F and Scherrmann JM: Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res 64: 3296-3301, 2004.
16. Qin XQ, Liang YG, Gao HZ, et al: Reversing mechanism of schizandrin A on multi-drug resistance of K562/ADR, HL60/ADR, MCF-7/ADR cell lines. Chin Pharmacol Bull 27: 329-334, 2011.
17. Huang M, Jin J, Sun H, and Liu GT: Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae. Cancer Chemother Pharmacol 62: 1015-1026, 2008.
18. Slaninová I, Brezinová L, Koubíková L and Slanina J: Dibenzocyclooctadiene lignans overcome drug resistance in lung cancer cells - study of structure-activity relationship. Toxicol In Vitro 23:1047-1054, 2009
19. Chai S, To KK and Lin G: Circumvention of multi-drug resistance of cancer cells by Chinese herbal medicines. Chin Med 5: 26, 2010.
20. Gupta PB, Onder TT, Jiang G, et al: Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138: 645-659, 2009.
21. Riccioni R, Dupuis ML, Bernabei M, et al: The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells Mol Dis 45: 86-92, 2010.
22. Ma I and Allan AL: The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev 7: 292-306, 2011.
23. Croker AK and Allan AL: Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ human breast cancer cells. Breast Cancer Res Treat 133: 75-87, 2012.
24. Chen YC, Chen YW, Hsu HS, et al: Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun 385: 307-313, 2009.
25. Januchowski R, Wojtowicz K and Zabel M: The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. Biomed Pharmacother 67: 669-680, 2013.
26. Kakarala M, Brenner DE, Korkaya H, et al: Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat 122: 777-785, 2010.
27. Li Y, Zhang T, Korkaya H, et al: Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res 16: 2580-2590, 2010.
28. Cioce M, Gherardi S, Viglietto G, et al: Mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like- and early progenitor-targeting drugs. Cell Cycle 9: 2878-2887, 2010.
29. Wickström M, Danielsson K, Rickardson L, et al: Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients. Biochem Pharmacol 73: 25-33, 2007.
30. Calabrese C, Poppleton H, Kocak M, et al: A perivascular niche for brain tumor stem cells. Cancer Cell 11: 69-82, 2007.
31. Atsumi N, Ishii G, Kojima M, Sanada M, Fujii S and Ochiai A: Podoplanin, a novel marker of tumor-initiating cells in human squamous cell carcinoma A431. Biochem Biophys Res Commun 373: 36-41, 2008.
32. He X, Marchionni L, Hansel DE, et al: Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. Stem Cells 27: 1487-1495, 2009.
33. Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E and Sipkins DA: Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 322: 1861-1865, 2008.
34. Lane SW, Scadden DT and Gilliland DG: The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 114: 1150-1157, 2009.
35. Vermeulen L, De Sousa E Melo F, van der Heijden M, et al: Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nature Cell Biol 12: 468-476, 2010.
36. Basak GW, Srivastava AS, Malhotra R and Carrier E: Multiple myeloma bone marrow niche. Curr Pharm Biotechnol 10: 345-346, 2009.
37. Ostman A: The tumor microenvironment controls drug sensitivity. Nat Med 18: 1332-1334, 2012.
38. Vinogradov S and Wei X: Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond) 7: 597-615, 2012.
39. Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.
40. Segers J, Di Fazio V, Ansiaux R, et al: Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature. Cancer Lett 244: 129-135, 2006.
41. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550, 2006.
42. Horsman MR and Siemann DW: Pathophysiologic effects of vasculartargeting agents and the implications for combination with conventional therapies. Cancer Res 66: 11520-11539, 2006.
43. Yang J and Weinberg RA: Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14: 818-829, 2008.
44. Polyak K and Weinberg RA: Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265-273, 2009.
45. Voulgari A and Pintzas A: Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 1796: 75-90, 2009.
46. Rattan R, Ali Fehmi R and Munkarah A: Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis. J Oncol 2012: 928127, 2012.
47. Singh A and Settleman J: EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29: 4741-4751, 2010.
48. Tang SN, Fu J, Nall D, Rodova M, Shankar S and Srivastava RK: Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics. Int J Cancer 131: 30-40, 2012.
49. Song Z, Yue W, Wei B, et al: Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer. PLoS One 6: e17687, 2011.
50. Merchant AA and Matsui W: Targeting Hedgehog - a cancer stem cell pathway. Clin Cancer Res 16: 3130-3140, 2010.
51. Singh BN, Fu J, Srivastava RK and Shankar S: Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS One 6: e27306, 2011.
52. Xia J, Chen C, Chen Z, Miele L, Sarkar FH and Wang Z: Targeting pancreatic cancer stem cells for cancer therapy. Biochim Biophys Acta 1826: 385-399, 2012.
53. Fan X, Khaki L, Zhu TS, et al: NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 28: 5-16, 2010.
54. Kondratyev M, Kreso A, Hallett RM, et al: Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer. Oncogene 31: 93-103, 2011.
55. Takahashi-Yanaga F and Kahn M: Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 16: 3153-3162, 2010.
56. Sarkar FH, Li Y, Wang Z, Kong D and Ali S: Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat 13: 57-66, 2010.
57. Arrieta O, González-De la Rosa CH, Aréchaga-Ocampo E, et al: Randomized phase II trial of all-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer. J Clin Oncol 28: 3463-3471, 2010.
58. Sze CI, Su WP, Chiang MF, Lu CY, Chen YA and Chang NS: Assessing current therapeutic approaches to decode potential resistance mechanisms in glioblastomas. Front Oncol 3: 59, 2013.